TMCnet News
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019WALTHAM, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced new data from two abstracts presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington, D.C. November 5 -10, 2019. “We are pleased to have presented the results of our completed renal impairment study at Kidney Week, which have been important in defining the appropriate doses for patients with renal insufficiency. These data support our current clinical programs as well as the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease where there is a high prevalence of nonsense mutation patients,” said Dr. Gregory Williams, Chief Operating Officer of Eloxx Pharmaceuticals. “We are advancing our Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis and we look forward to providing an update on our cystic fibrosis clinical trials and reporting additional top line cystinosis data later this quarter.” In a poster session titled “An open label-single dose, parallel-group study to evaluate the effects of renal impairment on the pharmacokinetics of ELX-02: Results from subjects with mild and moderate renal impairment,” Dr. Gregory Williams, Chief Operating Officer, Eloxx Pharmaceuticals reported that:
In a poster session titled “Cystinosis nonsense mutation read-through mediated by ELX-02 restores proteinfunction using in vitro and in vivo models,” Dr. Matthew Goddeeris, Executive Director of Research, Eloxx Pharmaceuticals reported that:
About Eloxx Pharmaceuticals Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx recently announced a new program focused on rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel. For more information, please visit www.eloxxpharma.com. Forward-Looking Statements Contact: Barbara Ryan SOURCE: Eloxx Pharmaceuticals, Inc. |